Torisel (temsirolimus)
by Jessica Langholtz
Published: Dec 3, 2009 3:19 pm
Published: Dec 3, 2009 3:19 pm
| Brand Name: | Torisel |
| Generic Name: | temsirolimus |
| Code Name: | |
| Company: | Wyeth |
| FDA Clinical Phase: | 2 |
Description:
Torisel, which is currently approved for treatment of advanced renal cell carcinoma, is being studied for treatment of multiple myeloma in combination with Velcade (bortezomib) and dexamethasone (Decadron). Torisel inhibits the mammalian target of rapamycin (mTOR), which is a critical protein for cancer cell growth.
Clinical Trials:
Currently, there are several open clinical studies involving Torisel.
Official Web site for Torisel: http://www.torisel.com/
Updated December 3, 2009
Related Articles:
- Velcade-Torisel Combination Proves Highly Effective In Multiple Myeloma Patients (ASH 2009)
- Torisel Achieves Little Response In Relapsed Multiple Myeloma Patients
- ASH 2008 – Perifosine Effective Against Multiple Myeloma In Combination With Dexamethasone-Revlimid And Dexamethasone-Velcade
- IMW 2009 – Elotuzumab And Panobinostat Clinical Trials With Velcade
- New Myeloma Drugs Target Different Mechanisms: Signaling Pathways
Leave a comment